All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | ROP-ET: Ropeginterferon alfa-2b for ET with limited treatment options
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Common treatments for the management of essential thrombocythemia (ET) include hydroxyurea, anagrelide, busulfan, and pipobroman. However, an increasing number of patients are experiencing intolerance, resistance, or comorbidities to these treatments, significantly limiting their available options going forward.
Ropeginterferon alfa-2b has shown efficacy in the treatment of polycythemia vera and is now being further investigated for its application in ET as part of the ROP-ET clinical trial. ROP-ET is a prospective, single-arm, phase III clinical trial evaluating ropeginterferon alfa-2b for the treatment of ET with limited treatment options.
The rationale and design for ROP-ET has recently been published in Annals of Hematology by Kiladjian et al. 1
The MPN Hub is pleased to summarize the study design of ROP-ET.
Your opinion matters
9 votes - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox